Enfermedad por reflujo no erosivo y acidez funcional

1. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definitionand classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900–1920; quiz 1943.

2. Gyawali CP, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut 2018;67:1351–1362.

3. Modlin IM, Hunt RH, Malfertheiner P, et al. Diagnosis and management of non-erosive reflux disease–the Vevey NERD Consensus Group. Digestion 2009;80:74–88.

4. Clouse RE, Richter JE, Heading RC, et al. Functional esophageal disorders. Gut 1999;45(Suppl 2):II31–II36.

5. Drossman DA, Corazziari E, Talley J, et al. Rome II: The functional gastrointestinal disorders. Diagnosis, pathophysiology and treatment. A multinational consensus. Lawrence, KS: Allen Press, 2000.

6. Fass R, Shapiro M, Dekel R, et al. Systematic review: protonpump inhibitor failure in gastro-oesophageal reflux disease–where next? Aliment Pharmacol Ther 2005;22:79–94.

7. Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology 2016. Epub ahead of print.

8. Eusebi LH, Ratnakumaran R, Yuan Y, et al. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut 2018;67:430–440.

9. El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2014;63:871–880.

10. Martinez SD, Malagon IB, Garewal HS, et al. Non-erosive reflux disease (NERD)–acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17:537–545.

11. Quigley EM. Non-erosive reflux disease, functional heartburn and gastroesophageal reflux disease; insights into pathophysiology and clinical presentation. Chin J Dig Dis 2006; 7:186–190.

12. Tefera L, Fein M, Ritter MP, et al. Can the combination of symptoms and endoscopy confirm the presence of gastroesophageal reflux disease? Am Surg 1997;63:933–936.

13. Johansson KE, Ask P, Boeryd B, et al. Oesophagitis, signs of reflux, and gastric acid secretion in patients with symptoms of gastro-oesophageal reflux disease. Scand J Gastroenterol 1986;21:837–847.

14. Ronkainen J, Aro P, Storskrubb T, et al. High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005; 40:275–285.

15. Zagari RM, Fuccio L, Wallander MA, et al. Gastro-oesophageal reflux symptoms, oesophagitis and Barrett’s oesophagus in the general population: the Loiano-Monghidoro study. Gut 2008; 57:1354–1359.

16. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41:131–137.

17. Yamasaki T, Fass R. Reflux hypersensitivity: a new functional esophageal disorder. J Neurogastroenterol Motil 2017; 23:495–503.

18. Fullard M, Kang JY, Neild P, et al. Systematic review: does gastro-oesophageal reflux disease progress? Aliment Pharmacol Ther 2006;24:33–45.

19. Labenz J, Nocon M, Lind T, et al. Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006;101:2457–2462.

20. Surdea Blaga T, Dumitrascu D, Galmiche JP, et al. Functional heartburn: clinical characteristics and outcome. Eur J Gastroenterol Hepatol 2013;25:282–290.

21. Zerbib F, Bruley des Varannes S, Simon M, et al. Functional heartburn: definition and management strategies. Curr Gastroenterol Rep 2012;14:181–188.

22. Knowles CH, Aziz Q. Visceral hypersensitivity in non-erosive reflux disease. Gut 2008;57:674–683.

23. Bredenoord AJ, Weusten BL, Timmer R, et al. Characteristics of gastroesophageal reflux in symptomatic patients with and without excessive esophageal acid exposure. Am J Gastroenterol 2006;101:2470–2475.

24. Emerenziani S, Sifrim D, Habib FI, et al. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut 2008; 57:443–447.

25. Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther 2004;20:81–88.

26. Yang M, Li ZS, Chen DF, et al. Quantitative assessment and characterization of visceral hyperalgesia evoked by esophageal balloon distention and acid perfusion in patients with functional  heartburn, nonerosive reflux disease, and erosive esophagitis. Clin J Pain 2010;26:326–331.

27. Hobson AR, Furlong PL, Aziz Q. Oesophageal afferent pathway sensitivity in non-erosive reflux disease. Neurogastroenterol Motil 2008;20:877–883.

28. Thoua NM, Khoo D, Kalantzis C, et al. Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. Aliment Pharmacol Ther 2008; 27:396–403.

29. Klauser AG, Heinrich C, Schindlbeck NE, et al. Is long-term esophageal pH monitoring of clinical value? Am J Gastroenterol 1989;84:362–366.

30. DeMeester TR, Wang CI, Wernly JA, et al. Technique, indications, and clinical use of 24 hour esophageal pH monitoring.  J Thorac Cardiovasc Surg 1980;79:656–670.

31. Fass R. Functional heartburn: what it is and how to treat it. Gastrointest Endosc Clin N Am 2009;19:23–33, v.

32. Hershcovici T, Zimmerman J. Functional heartburn vs. Nonerosive reflux disease: similarities and differences. Aliment Pharmacol Ther 2008;27:1103–1109.

33. Shapiro M, Green C, Bautista JM, et al. Functional heartburn patients demonstrate traits of functional bowel disorder but lack a uniform increase of chemoreceptor sensitivity to acid. Am J Gastroenterol 2006;101:1084–1091.

34. Savarino E, Pohl D, Zentilin P, et al. Functional heartburn has more in common with functional dyspepsia than with nonerosive reflux disease. Gut 2009;58:1185–1191

35. de Bortoli N, Frazzoni L, Savarino EV, et al. Functional heartburn overlaps with irritable bowel syndrome more often than GERD. Am J Gastroenterol 2016;111:1711–1717.

36. Hershcovici T, Fass R. GERD: are functional heartburn and functional dyspepsia one disorder? Nat Rev Gastroenterol Hepatol 2010;7:71–72.

37. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007;5:4–16.

38. Fiocca R, Mastracci L, Riddell R, et al. Development of consensus guidelines for the histologic recognition of microscopic esophagitis in patients with gastroesophageal reflux disease: the Esohisto project. Hum Pathol 2010;41:223–231.

39. Yerian L, Fiocca R, Mastracci L, et al. Refinement and reproducibility of histologic criteria for the assessment of microscopic lesions in patients with gastroesophageal reflux disease: the Esohisto Project. Dig Dis Sci 2011;56:2656–2665.

40. Savarino E, Zentilin P, Mastracci L, et al. Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn. J Gastroenterol 2013; 48:473–482.

41. Kandulski A, Jechorek D, Caro C, et al. Histomorphological differentiation of non-erosive reflux disease and functional heartburn in patients with PPI-refractory heartburn. Aliment Pharmacol Ther 2013;38:643–651.

42. Madan K, Ahuja V, Gupta SD, et al. Impact of 24-h esophageal pH monitoring on the diagnosis of gastroesophageal reflux disease: defining the gold standard. J Gastroenterol Hepatol 2005;20:30–37.

43. Sweis R, Fox M, Anggiansah A, et al. Prolonged, wireless pHstudies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. Neurogastroenterol Motil 2011;23:419–426.

44. Penagini R, Sweis R, Mauro A, et al. Inconsistency in the diagnosis of functional heartburn: usefulness of prolonged Wireless pH monitoring in patients with proton pump inhibitor refractory gastroesophageal reflux disease. J Neurogastroenterol Motil 2015;21:265–272.

45. Bautista JM, Wong WM, Pulliam G, et al. The value of ambulatory 24 hr esophageal pH monitoring in clinical practice in patients who were referred with persistent gastroesophageal reflux disease (GERD)-related symptoms while on standard doce anti-reflux medications. Dig Dis Sci 2005;50:1909–1915.

46. Vela MF, Camacho-Lobato L, Srinivasan R, et al. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 2001;120:1599–1606.

47. Wiener GJ, Richter JE, Copper JB, et al. The symptom index: a clinically important parameter of ambulatory 24-hour esophageal pH monitoring. Am J Gastroenterol 1988;83:358–361.

48. Weusten BL, Roelofs JM, Akkermans LM, et al. The symptomassociation probability: an improved method for symptom analysis of 24-hour esophageal pH data. Gastroenterology 1994;107:1741–1745.

49. Singh S, Richter JE, Bradley LA, et al. The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci 1993; 38:1402–1408.

50. Slaughter JC, Goutte M, Rymer JA, et al. Caution about overinterpretation of symptom indexes in reflux monitoring for refractory gastroesophageal reflux disease. Clin GastroenterolHepatol 2011;9:868–874.

51. Kavitt RT, Higginbotham T, Slaughter JC, et al. Symptom reports are not reliable during ambulatory reflux monitoring. Am J Gastroenterol 2012;107:1826–1832.

52. Savarino E, Zentilin P, Tutuian R, et al. The role of nonacid reflux in NERD: lessons learned from impedance-pH monitoring in 150 patients off therapy. Am J Gastroenterol 2008;103:2685–2693.

53. Roman S, Gyawali CP, Savarino E, et al. Ambulatory reflux monitoring for diagnosis of gastro-esophageal reflux disease: update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterol Motil 2017;29:1–15.

54. de Bortoli N, Martinucci I, Savarino E, et al. Association between baseline impedance values and response proton pump inhibitors in patients with heartburn. Clin Gastroenterol Hepatol 2015;13:1082–1088 e1.

55. Frazzoni M, Savarino E, de Bortoli N, et al. Analyses of the postreflux swallow-induced peristaltic wave index and nocturnal baseline impedance parameters increase the diagnostic yield of impedance-pH monitoring of patients with reflux disease. Clin Gastroenterol Hepatol 2016;14:40–46.

56. Frazzoni M, de Bortoli N, Frazzoni L, et al. Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn. J Gastroenterol 2017;52:444–451.

57. Martinucci I, de Bortoli N, Savarino E, et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics

of functional heartburn. Neurogastroenterol Motil 2014;

26:546–555.

58. Frazzoni M, Bertani H, Manta R, et al. Impairment of chemical clearance is relevant to the pathogenesis of refractory reflux oesophagitis. Dig Liver Dis 2014;46:596–602.

59. Frazzoni L, Frazzoni M, de Bortoli N, et al. Postreflux swallowinduced peristaltic wave index and nocturnal baseline impedance can link PPI-responsive heartburn to reflux better than acid

exposure time. Neurogastroenterol Motil 2017;29.

60. Farre R, Blondeau K, Clement D, et al. Evaluation of oesophageal mucosa integrity by the intraluminal impedance technique. Gut 2011;60:885–892.

61. Kessing BF, Bredenoord AJ, Weijenborg PW, et al. Esophageal acid exposure decreases intraluminal baseline impedance levels. Am J Gastroenterol 2011;106:2093–2097.

62. Kandulski A, Weigt J, Caro C, et al. Esophageal intraluminal baseline impedance differentiates gastroesophageal reflux disease from functional heartburn. Clin Gastroenterol Hepatol 2015;13:1075–1081.

63. Zhong C, Duan L, Wang K, et al. Esophageal intraluminal baseline impedance is associated with severity of acid reflux and epithelial structural abnormalities in patients with gastroesophageal reflux disease. J Gastroenterol 2013;48:601–610.

64. Woodland P, Al-Zinaty M, Yazaki E, et al. In vivo evaluation of acid-induced changes in oesophageal mucosa integrity and sensitivity in non-erosive reflux disease. Gut 2013; 62:1256–1261.

65. Patel A, Wang D, Sainani N, et al. Distal mean nocturnal baseline impedance on pH-impedance monitoring predicts reflux burden and symptomatic outcome in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2016;44:890–898.

66. van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol 2014; 12:1815–1823 e2.